Molecular Classification of Endometrial Carcinomas

子宫内膜癌的分子分类

• 批准号: 6877995
• 负责人: JEFFREY ALLEN BOYD
• 金额: $ 46.47万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-26 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6877995
• 关键词: cancer registry /resource; clinical research; female; gene expression; gene expression profiling; human data; human tissue; immunocytochemistry; laser capture microdissection; microarray technology; molecular genetics; molecular oncology; neoplasm /cancer classification /staging; neoplasm /cancer genetics; northern blottings; polymerase chain reaction; prognosis; uterus neoplasms; western blottings

DESCRIPTION (provided by applicant): Endometrial carcinoma (EC) is a highly heterogeneous disease entity, consisting of at least two categories defined by distinct histopathological and clinical features. In addition to the traditionally defined type I (association with hyperestrogenism, low grade endometrioid histology, and good prognosis) and type II (no well defined epidemiologic risk factors, high grade papillary serous or clear cell histologies, and poor prognosis) tumors, there may also exist a poorly defined third category, consisting of endometrioid tumors of high architectural or nuclear grade and moderate to poor prognosis. Often it is difficult to classify an individual case of EC with respect to one or another of these general categories. This heterogeneity in clinical outcome presumably reflects differences in the underlying molecular genetic characteristics of individual cancers, but the molecular genetic basis of EC remains largely obscure. Thus, the long term goal of this project is to address the hypothesis that a comprehensive molecular genetic classification of EC will improve our ability to classify individual cases of EC and predict response to therapy and clinical outcome. Furthermore, elucidation of the molecular determinants of these clinical outcome parameters should provide substantial insights into the biological basis of endometrial tumorigenesis, as well as suggest potential new targets or strategies for EC therapy. We propose that this goal may be accomplished through the systematic application of new, comprehensive molecular screening methodologies, specifically, the use of microarrays for genome-wide gene expression analyses, together with a large EC tissue resource linked to extensive surgical, histopathological, and clinical data. The specific aims of this project are to: 1) obtain RNA expression profiles of a large number of ECs using oligonucleotide expression arrays to identify subgroups assembled by expression characteristics; 2) define distinct molecular subsets of EC that will predict response to therapy and survival, by correlating these molecular observations with clinical outcomes and pathological states; and 3) confirm and refine observations from specific aims one and two using targeted assays and tissue-based approaches.

描述（由申请人提供）：子宫内膜癌（EC）是一种高度异质性的疾病实体，由至少两种由不同的组织病理学和临床特征定义的类别组成。除了传统定义的I型（与高雌激素血症、低级别类胶质瘤组织学和良好预后相关）和II型（没有明确的流行病学危险因素、高级别乳头状浆液性或透明细胞组织学和不良预后）肿瘤外，还可能存在定义不明确的第三类肿瘤，包括高结构或核级别和中度至不良预后的类胶质瘤。通常很难根据这些一般类别中的一个或另一个来对个别的EC病例进行分类。这种临床结果的异质性可能反映了个体癌症的潜在分子遗传学特征的差异，但EC的分子遗传学基础仍然很不清楚。因此，本项目的长期目标是解决这一假设，即EC的综合分子遗传学分类将提高我们对EC个体病例进行分类并预测对治疗和临床结果的反应的能力。此外，这些临床结果参数的分子决定因素的阐明应提供实质性的见解子宫内膜肿瘤发生的生物学基础，以及建议潜在的新的目标或EC治疗策略。我们建议，这一目标可以通过系统地应用新的，全面的分子筛选方法，具体地说，使用微阵列进行全基因组基因表达分析，连同大量的EC组织资源，广泛的手术，组织病理学和临床数据。本项目的具体目标是：1）使用寡核苷酸表达阵列获得大量EC的RNA表达谱，以识别由表达特征组装的亚组; 2）通过将这些分子观察与临床结果和病理状态相关联，定义EC的不同分子亚组，其将预测对治疗的反应和存活;以及3）使用靶向测定和基于组织的方法确认和完善来自具体目标一和二的观察结果。